london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Dont treat and extend' dosing of intravitreal ranibizumab therapy for neovascular age-related macular degeneration

Poster Details

First Author: S.Ch'ng UK

Co Author(s):    S.S. Deol   P. Tesha               0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate 1 year outcomes for neovascular age-related macular degeneration treated using a 'Don't Treat and Extend' dosing regimen with ranibizumab.


Lincoln County Hospital, Lincolnshire, UK


Retrospective study of 90 eyes of 85 patients with nAMD treated with intravitreal ranibizumab with 1 year follow up. All patients recieved initial three monthly injections. Follow up was extended by 2 weeks per visit depending on results of optical coherence tomogprahy and clinical findings. Maximum follow-up was 12 weeks.


8.8 letters average improvement (comparable to 11.3 ANCHOR, 7.2 MARINA, and 9.3 PrONTO). Average number of treatments was 5.3, compared to 5.6 in PrONTO.


'Dont Treat and Extend' dosing regimen delivers good visual outcomes comparable to published data. This regimen may allow patients undergoing nAMD to be followed up less frequently.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy